GPT and cryohydrocytosis: Results of this clinical trial demonstrated that bLf therapy allows improvement in lipid peroxidation and alanine aminotransferase (ALT) levels suggesting its oral administration as a promising therapeutic approach for suppressing oxidative stress and inflammation in patients with CHC non-responders to antiviral therapy.